|
|
|
Welcome to the Quality Counts. For those health conscious consumers and medical professionals that are looking to purchase nutritional supplements, vitamins, herbs, learning about medications, losing weight, health food, low carbs, high protein nutrition, and exercise, you have come to the right place. Quality Counts serves both the medical practitioner and consumer interested in nutritional therapy and alternative medicine.
Home >
Anti-aging Research > Proscar/Avodart
Avodart (dutasteride)
Related Topics:
Where to purchase:
Alternative News:
- See saw palmetto
- Relieve Common Men’s Condition with Saw Palmetto Extract - Healthwell Exchange Daily News, 9/16/04 -
"Comparison trials found its effects to be similar to those of finasteride and tamsulosin ... however,
while some men using the standard medications experienced sexual dysfunction as a side effect, men using the herbal extract did not" - See
iHerb
 or
Vitacost
saw palmetto products.
News & Research:
-
Avodart (dutasteride) - rxlist.com - "AVODART (dutasteride) is a
synthetic 4-azasteroid compound that is a selective inhibitor of both the
type 1 and type 2 isoforms of steroid 5a-reductase (5AR), an intracellular
enzyme that converts testosterone to 5a-dihydrotestosterone (DHT)"
-
Dutasteride Is Seen to Curtail Cancer Left in Prostate - NYTimes.com,
1/23/12 - "Two previous studies suggested that
dutasteride and a similar drug, finasteride, could actually protect men from
prostate cancer ... Three years later, the cancer had progressed in 54 men in
the dutasteride group, or 38 percent, and in 70 men in the placebo group, or 48
percent"
-
The Impact of Current BPH Treatment on Sexual Function - Medscape, 10/13/11
- See table one. Some of those medications were less than the placebo.
For example, Alfuzosin had a 3% ED rate but the placebo was 4%. The
article didn't cover
gynecomastia which can be a problem with BPH treatments. Some studies
support letrozole to prevent
gynecomastia. I take a quarter
tablet every other day.
-
Popular
drugs for common male health problems can affect their sexual health -
Science Daily, 3/7/11
-
Drugs
for hair loss and benign prostatic hyperplasia may result in loss of libido,
erectile dysfunction in men - Science Daily, 1/11/11 -
"5a-reductase inhibitors (5a-RIs), while improving
urinary symptoms in patients with benign prostatic hyperplasia (BPH) and
possible hair loss prevention, produces significant adverse effects in some
individuals including loss of libido, erectile dysfunction (ED), ejaculatory
dysfunction and potential depression" - Note: That goes back and
forth. One study claimed that finasteride improved sex after after six
months of taking it. Regarding gynaecomastia, if you're taking low dose
letrozole to increase testosterone and to prevent aromatization it many also
help prevent gynaecomastia.
-
Prostate Drug May Not Dim Sex - WebMD, 6/26/07 - "Six months after the men started taking their assigned drugs, the survey
scores were about three points higher for the men taking Proscar. By the end
of the study, that gap narrowed to about two points"
-
Prostate Drug Doesn't Limit Sexual Function In Most Men - Science Daily,
7/19/07 - "The study suggests that finasteride will
cause little or no sexual dysfunction for most men who decide to take it"
-
Ask a Medical Question - Can letrozole cure gynecomastia - JustAnswer -
"Letrozole may be effective in preventing and
reversing the gynaecomastia provided it is used early enough in steroid
induced gynaecomastia" - See letrozole at
OffshoreRX.com.
I believe the recommended dose is something like a quarter tablet every
three days but don't quote me on it. That's what I take.
-
PSA test
better predicts cancer in men taking prostate-shrinking drug - Science
Daily, 12/16/10 - "Dutasteride lowers PSA levels by about half within six
months. But the researchers found that even a slight rise in PSA levels among
men taking the drug was a stronger indicator of prostate cancer, particularly
aggressive tumors that require early diagnosis and treatment, than rising PSA
levels in men who took a placebo ... dutasteride reduced the risk of a prostate
cancer diagnosis by 23 percent. Dutasteride appears to keep tumors small or
shrink them to the point that they are less likely to be detected by a biopsy
... Over four years, PSA levels increased in 72 percent of men taking a placebo
and only 29 percent of men taking dutasteride, the data show"
-
FDA
Approves Dutasteride/Tamsulosin Combo Pill for BPH - Medscape, 6/18/10 -
"daily use of the drug combination yielded significantly
greater relief of BPH symptoms compared with either 0.5 mg dutasteride or 0.4 mg
tamsulosin alone, as measured by point changes on the International Prostate
Symptom scale from baseline (mean Δ, −6.2 vs −4.9 and −4.3; P < .001 for both).
The difference was observed by month 9 and continued through month 24"
-
The Effect
of Short-term Dutasteride Intake in Early-stage Prostate Cancer: Analysis of 148
Patients Who Underwent Three-dimensional Prostate Mapping Biopsy - Urology.
2010 May 14 - "transperineal three-dimensional mapping (TP-3DM) biopsy ... We
observed a 24.3% decrease in the proportion of upstaging and/or upgrading of
prostate cancer in men who received dutasteride at least 3 months before 3D
prostate TP-3DM biopsy. Thus, the effect of dutasteride on prostate cancer may
have implications for its potential use as a secondary chemoprevention agent" -
See dutasteride at
OffshoreRX.com.
-
Avodart May Lower Prostate Cancer Risk - WebMD, 3/31/10 -
"those who took
the drug Avodart had a 23% lower risk of being diagnosed with prostate cancer
over four years of treatment, compared to men who did not take the drug" - See Avodart (dutasteride) at
OffshoreRX.com.
-
Combination therapy more effective for enlarged prostate - Science Daily,
3/2/10 - "On the strengths of both dutasteride and tamsulosin, participants
reported fewer symptoms, and we observed a 25 percent reduction in prostate
volume ... subjects who received the combination therapy also showed a 50
percent reduction of prostate-specific antigen (PSA), a protein produced by both
cancerous and noncancerous prostate tissue ... Compared with tamsulosin alone,
the combination of drugs reduced the incidence of acute urinary retention by 67
percent and reduced the need for BPH-related surgery by 70 percent"
-
Dutasteride Reduces Risk for Biopsy-Detectable Prostate Cancer in Men at
Increased Risk - Doctor's Guide, 12/1/09 - "Compared
with placebo, active treatment also showed significantly lower risks for
(respectively) HG-PIN (5.4% vs 3.5%; RRR, 34%; P = .0053), ASAP (5.1% vs 3.6%;
RRR, 28%; P = .0274), AUR (7.1% vs 1.4%; RRR, 80.4%; P < .0001), BPH-related
surgery (5.7% vs 1.4%; RRR 75.6%; P < .0001), and UTI (9.6% vs 5.8%; RRR, 40.8%;
P < .0001) ... Similarly, there were significant reductions for mean prostate
volume (18.7% increase vs 16.9% decrease; P < .0001) and IPSS (+1.14 vs -0.6; P
< .0001), and slightly fewer high-grade tumours (Gleason score, 7-10) in the
dutasteride group (7.5% vs 7.0%) ... These benefits were accompanied by
significantly more frequent dutasteride-related adverse events (12% vs 19%; P <
.0001), with dutasteride treatment showing increased frequencies of decreased
libido (2.8% vs 5.5%), impotence (7.7% vs 10.9%), ejaculation disorders (0.5% vs
2.4%), and breast disorders (1.9% vs 3.5%)"
-
Diet, Drugs May Stop Prostate Cancer - WebMD, 9/24/07
-
Diet And
Medications May Assist Prevention Of Prostate Cancer - Science Daily,
9/24/07 - "dutasteride, has reduced by 50 percent the
number of cancerous biopsies among men with benign prostatic hypertrophy ... In
one study of selenium, the incidence of prostate cancer was reduced by 49
percent over ten years ... Data already suggests novel uses of statins, commonly
prescribed cholesterol-lowering agents, and insulin modulating drugs, such as
metformin or the glitazones"
-
Treatment Found To Reverse Hair Loss - Science Daily, 6/11/07 -
"one of each pair of twins was given 0.5
mg/day of the medication, the other receiving a placebo ... After both 6 and
12-month intervals, hair loss was found to not only have been halted in twins
using dutasteride, but hair growth was actively improved"
Abstracts:
-
Dutasteride
Improves Outcomes of Benign Prostatic Hyperplasia When Evaluated for Prostate
Cancer Risk Reduction: Secondary Analysis of the REduction by Dutasteride of
Prostate Cancer Events (REDUCE) Trial - Urology. 2011 Jul 14 -
"During the
4-year study, the International Prostate Symptom Score increased in
placebo-treated patients, while dutasteride-treated patients had a stabilized or
decreased International Prostate Symptom Score and improved BPH Impact Index and
quality of life due to urinary symptom scores across all prostate volume
quintiles (including prostate glands smaller than those studied in previous
dutasteride trials). 48 months, the incidence of acute urinary retention or
BPH-related surgery was significantly less in the dutasteride group (2.5%) than
in the placebo group (9%) overall (P < .001) and in each baseline prostate
volume quintile (P < .01)"
-
Effect of
dutasteride, tamsulosin and the combination on patient-reported quality of life
and treatment satisfaction in men with moderate-to-severe benign prostatic
hyperplasia: 4-year data from the CombAT study - Int J Clin Pract. 2010 May
7 - "Subjects were randomised to receive 0.5 mg dutasteride, 0.4 mg tamsulosin
or the combination once daily for 4 years ... At 4 years, combination therapy
resulted in significantly superior improvements from baseline in BII and IPSS Q8
than either monotherapy; these benefits were observed from 3 months onwards
compared with dutasteride and from 9 months (BII) or 12 months (IPSS Q8) onwards
compared with tamsulosin. Also at 4 years, the PPSM questionnaire showed that a
significantly higher proportion of patients was satisfied with, and would
request treatment with, combination therapy compared with either monotherapy.
Conclusions: Combination therapy (dutasteride plus tamsulosin) provides
significantly superior improvements in patient-reported quality of life and
treatment satisfaction than either monotherapy at 4 years in men with
moderate-to-severe BPH symptoms" - See dutasteride at
OffshoreRX.com.
-
Association of Sexual Dysfunction With Lower Urinary Tract Symptoms of BPH
and BPH Medical Therapies: Results From the BPH Registry - Urology. 2009
Jan 21 - "The severity of lower urinary tract
symptoms (LUTS) has correlated with erectile dysfunction (ED) and
ejaculatory dysfunction (EjD) ... The alpha(1A)-subtype nonsuperselective
quinazoline alpha(1)-blockers alfuzosin, doxazosin, and terazosin appeared
to be associated with better ejaculatory function than were the
alpha(1A)-subtype superselective sulfonamide alpha(1)-blocker tamsulosin,
5alpha-reductase inhibitors, and alpha(1)-blocker plus 5alpha-reductase
inhibitor combination therapy"
-
Effect of Dutasteride
on Intraprostatic Androgen Levels in Men With Benign Prostatic Hyperplasia
or Prostate Cancer - Urology. 2008 Aug 19 - "The
results of our study have shown that dutasteride provides near-maximal
suppression of both serum and intraprostatic DHT levels in men with benign
prostatic hyperplasia or prostate cancer at all points assessed"
-
The Rationale for
Inhibiting 5alpha-Reductase Isoenzymes in the Prevention and Treatment of
Prostate Cancer - J Urol. 2008 Feb 14 - "The 2
5alpha-reductase inhibitors currently clinically available are finasteride,
a type 2 5alpha-reductase inhibitor, and dutasteride, a dual
5alpha-reductase inhibitor. Dual inhibition by dutasteride has been shown to
translate into a greater degree and consistency of dihydrotestosterone
suppression compared with finasteride. The Prostate Cancer Prevention Trial
showed that finasteride significantly decreased the 7-year risk of prostate
cancer in men with prostate specific antigen 3.0 ng/ml or less, while the
ongoing Reduction by Dutasteride of Prostate Cancer Events study is
assessing whether dutasteride decreases the risk of biopsy detectable
prostate cancer in men with prostate specific antigen 2.5 to 10 ng/ml and a
previous negative biopsy"
-
The importance of dual 5alpha-reductase inhibition in the treatment of male
pattern hair loss: results of a randomized placebo-controlled study of
dutasteride versus finasteride - J Am Acad Dermatol. 2006
Dec;55(6):1014-23 - "Dutasteride
increased target area hair count versus placebo in a dose-dependent fashion
and dutasteride 2.5 mg was superior to finasteride at 12 and 24 weeks"
- Note: Dutasteride is Avodart®.
See dutasteride at OffshoreRX.com
or
International Antiaging Systems.
Related Searches:
70520
|
